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Abstract. A cytokine which augments the expression of major histocompatibility complex
(MHC) I antigens on K562 and gastric carcinoma tumour (HR) cells, has been isolated from the 
culture supernatant of Concanavalin-A (Con-A) activated human peripheral blood mononuclear 
cells. The factor, termed MHC augmenting factor (MHC-AF) has been partially purified by 
Sephadex G-100 column chromatography, preparative isoelectric focusing and HPLC with 
ion-exchange as well as sizing columns. MHC-AF activity is associated with a 35 kDa molecule 
which has pI of 6·0. Interferon (IFN)-α, ß, tumour necrosis factor (TNF), Interleukin (IL)-2, 
IL-4, IL-5 and IL-7 had no significant effect in MHC-AF bioassay, but IFN-γ had significant 
MHC-AF activity. Antibodies to IFN-α, IFN-ß and TNF-α did not block the activity of 
MHC-AF, but anti-IFN-y antibodies could partially neutralize the activity. However, unlike 
IFN-γ, MHC-AF activity was resistant to pH 2·0 treatment. Purified MHC-AF preparations 
did not have any activity in WISH cell/encephalo myocarditis virus (EMC) IFN bioassays. In 
addition, anti-IFN-y affinity column did not retain MHC-AF activity. These results indicate that 
a MHC-AF distinct from IFN-γ, is produced by activated human mononuclear cells. 
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1.  Introduction 
 
Class I and class II molecules encoded in the major histocompatibility complex (MHC) 
play a central role in immune cell interactions. The helper subset of T-lymphocytes 
recognize antigens presented by the class II MHC antigens on antigen presenting cells 
(Rosenthal and Shevach 1973). Class I MHC molecules associate with and present 
antigenic peptides to the cytotoxic T-lymphocytes (CTL) (Zinkernagal and Doherty 
1979). Antigen receptors on CTL recognize antigenic peptides on target cells, in 
association with class I MHC antigens, as a result, CTL-mediated target lysis is 
restricted in activity by class I MHC molecules as well as antigens. Natural killer (NK) 
cells comprise another class of cytotoxic lymphocytes which can lyse allogeneic and 
even xenogeneic target cells (Sarin and Saxena 1989), and the class I or II MHC 
antigens are not required for NK recognition of target cells. Nonetheless, alternations 
in the quantitative expression of class I MHC antigens on some target cells have been 
shown to change their susceptibility to NK cell mediated lysis. An inverse relationship 
has often been observed between the amount of the class I MHC antigen expressed on 
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tumour cells and their susceptibility to NK or lymphokine activated Killer (LAK) cells 
(Harel-Bellan et al 1986; Storkus et al 1987), though, exceptions to this trend have also 
been reported (Gorelik et al 1988; Leiden et al 1989). 
Both NK as well as T cells participate in immunesurveillance mechanisms and, since the 
class I MHC antigen expression on tumour target cells may determine their susceptibility 
to these immunesurveillance mechanisms, factors which regulate the expression of the 
class I MHC antigens on tumour cells, may determine the fate of a tumour in vivo. 
Many factors are known to modulate class I MHC antigen expression on tumour 
cells. These include cytokines such as IFN and TNF (Wiebke et a11990), in vivo passage 
of tumour cells (Piontek et al 1985) and treatment with inducers of differentiation, such 
as phorbol esters and sodium butyrate (Dokhelar et a11982, 1984). We have described 
the presence of a factor in culture supernatants of rat spleen cells, which enhances class 
I MHC antigen expression on YAC tumour cells and renders them resistant to NK cells 
(Saxena 1987; Saxena et al 1989). This factor which was termed NK lysis resistance 
including factor (NK-RIF) has been partially purified and characterized (Saxena 1987; 
Saxena et al 1988a,b, 1989, 1992). Rat NK-RIF is distinct from IFN, since the former 
has no anti-viral activity and its activity is not neutralized by anti-IFN antibodies 
(Saxena et al 1988a,b). In the present communication, we report the partial purification 
and characterization of a human factor which augments the expression of class I MHC 
antigens on some tumour cell lines. The factor termed MHC-AF is a 35 kDa molecule, 
with a pI of 6·0 and appears to be distinct from IFN or other known cytokines. 
 
2.  Materials and methods  
 
2.1    Reagents 
 
Various cytokines used in this study were obtained as gifts from the following sources: 
IL-2 was kindly provided by Cetus Chiron (Emeryville, CA); IL-12, Hoffmann LaRoche 
(Nutley, NJ, USA); IL-4 and IL-7 by sterling Drug Inc. (Malvern, PA, USA); IL-6 by 
Sandoz (Vienna, Austria); IFN-γ by Roussel CLAF (Romainville, France); and TNF-α by 
Knoll Pharmaceuticals (Whippany, NJ, USA). The hybridoma cell lines HB99 (secreting 
anti class I MHC Mab) and HB8291(secreting anti human IFN-γ Mab) were obtained from 
American Type Cell Culture (ATCC), Bethesda, Md, USA. Reagents for affinity column 
were purchased from BioProbe, International Ltd., Tustin, Ca, USA. Reagents for gel 
filtration and isoelectric focusing were obtained from Sigma (St. Louis, Mo, USA). 
 
2.2  Culture supernatants from Con-A—activated human peripheral blood mononuclear 
cells (HPBMC) 
 
HPBMC were isolated by Ficoll Hypaque density gradient centrifugation (Boyum 
1974). Cells derived from Leukaphereses of normal blood donors (Central Blood Bank, 
Pittsburgh, PA, USA) were diluted 20-fold in cold RPMI 1640 medium and 20 ml 
alliquots were layered on Lymphoprep solution (density 1·077 g/ml, Sigma) and 
centrifuged at 600g for 15 min. HPBMCs were removed from the interphase, washed 
three times with RPMI medium and cultured at a concentration of 5 x 106 cells/ml, in 
RPMI-1640 medium supplemented with 5% fetal calf serum (FCS), glutamine 
(300 µg ml) and 50 µg ml penicillin-streptomycin (complete medium, CM). Con-A
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(Sigma, St Louis, Mo, USA) was added at a final concentration of 5 µg/ml and 
supernatants were collected by centrifugation (2000 g for 15 min) after 3 days. 
 
2.3  Initial processing of Con-A culture supernatants 
 
Con-A supernatants were generally processed in batches of 1 to 4 liters. For each liter of 
supernatant maintained at 4°C, 599 g of ammonium sulphate was added gradually and 
the supernatant allowed to stand overnight at 4°C. Precipitated proteins were pelleted 
by centrifugation at 10,000 g for 20 min and resuspended in 0·1 M glycine-HCl buffer 
pH 2.0. The solution was dialyzed against the pH 2.0 buffer for two days and then 
neutralized to pH 7.0 by using I0 N NaOH. Any insoluble material present at this stage 
was removed by centrifugation, and the solution was concentrated on an Amicon 3K 
membrane filter to about 30 ml for each 1 liter of the starting material. 
 
2.4  Sephadex column chromatography 
 
A column of Sephadex G-100 (5 x 115 cm) was used and in each run 30 ml of the 
concentrates obtained by the processing of the culture supernatant, was fractionated 
on the column. The column was run at 4°C at a flow rate of 1ml/min using phosphate 
buffered saline (PBS). 
 
2.5  Preparative isoelectric focusing (IEF) 
 
Fractions of Sephadex G-100 column, with MHC-AF activity were pooled, concen-
trated and dialyzed against 1% glycine and fractionated by IEF by the procedure 
described elsewhere (Saxena 1987). IEF fractions were dialyzed against PBS and 
assayed for MHC-AF activity. Active fractions were pooled and concentrated using 
Amicon 3K membrane filters. 
 
2.6  HPLC fractionation 
 
An analytical anion-exchange HR8 HPLC column (Waters) and a sizing HPLC 
column PP125 (Waters) were used along with a Waters system HPLC equipment. 
Prior to fractionation on a HR8 column, the pooled IEF fractions with MHC-AF 
activity were dialyzed against 10 mM Tris-HCl buffer pH 8·2. The material absorbed 
on the column was eluted in a gradient of 20 to 100% (v/v) of 0.5 N NaCI in 10 mM 
Tris-HCl buffer pH 8·2. Column fractions were filter sterilized and assayed for MHC-
AF activity. Aliquots (0·2 ml) of the material eluted from the column and containing
MHC-AF activity were then applied to a PP125 column and PBS was used as eluting 
buffer. Fractions were assayed for MHC-AF activity after filter sterilization. 
 
2.7  MHC-AF bioassay 
 
HR cell line derived from a gastric carcinoma metastatic to the liver and established in our 
laboratory (Shimizu et al 1991) was specially sensitive to the effect of MHC-AF. In the 
present study, we have used both K562 and HR cells interchangeably for the bioassay of 
MHC-AF activity. The tumour cells cultured at 0·1 x 106 cells/ml in RPMI-1640 CM 
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(for K562) or MEM CM (for HR cells), in the presence of the desired concentrations of 
the test agents, for 2 to 3 days. At the end of the culture, cells were harvested and stained 
for class I MHC antigens. Culture supernatant of HB99 hybridoma was used as a source of 
a mouse monoclonal antibody (Mab) reactive to a non-polymorphic region of class I MHC 
antigens. Control or treated cell pellets were suspended in 50µl of the HB99 culture 
supernatants and incubated for 15 min at 4°C. Cells were washed once with cold PBS and 
suspended in 50µl of rabbit anti mouse Ig-FITC at 1: 100 dilution. After 15 min incubation 
at 4°C, cells were washed and fixed on 0·1 ml of a 1% (w/v) para-formaldehyde in PBS. 
Stained and fixed cells were analysed in flowcytometer. HR or K562 cells treated with 
second antibody alone did not show significant nonspecific staining. For K562 tumour 
cells, the data are presented as the percentage of cells becoming positive for class I MHC 
antigens after MHC-AF treatment. For HR cells, which show low but significant basal 
expression of class I MHC antigens, the increase in the expression of class I MHC 
antigens was assessed by the increase in the mean fluorescence intensity (MFI). 
 
2.8  IFN bioassay 
 
Anti-viral bioassay for IFN was performed using WISH cell/EMC system by the proce-
dure described before (Saxena et al 1988b). Briefly, 3 x 104, WISH cells in 0.2 ml of MEM 
complete medium, were plated in 96-well fiat-bottom tissue culture plates, in the presence 
of desired concentrations of the test agents. After 20 h, 10 µl of an appropriately diluted 
EMC virus preparation was added to each assay well. After two days, when untreated 
WISH cells were totally lysed by EMC, the level of protection in treated WISH cells was 
assessed under the microscope. One unit of IFN corresponded to half protection of WISH 
cells. For better quantitation, WISH cells were stained with 1% crystal violet in 70% 
ethanol as described before (Saxena et al 1988b). After washing the wells, dye was eluted in 
0.2 ml of methanol and the absorbance read in an ELISA reader using a 540 nm filter. 
 
2.9  Anti-IFN affinity column 
 
Anti-human IFN-γ monoclonal antibodies were isolated from the culture supernatant 
of hybridoma HB 8291 (ATCC), by using Avid Al affinity column (BioProbe, Interna-
tional Ltd., Tustin, Ca, USA). This antibody was coupled to a solid base in a cartridge: 
column using Hydrazide Avid Chrom cartridge system (Bio Probe International Ltd., 
Tustin, Ca, USA). A total of 2·5 mg of antibody was immobilized on the column, which 
could theoretically bind 10 x 106 units of IFN-γ. Efficacy of this column to remove 
IFN-γ was tested by placing different amounts of IFN-γ on the column. The highest 
amount of IFN-γ tested (10 units) was totally retained by the column. The column 
could be used repeatedly after removing the bound material by washing with glycine-
HCl buffer at pH 2·0 and reequilibrating the column in PBS. 
 
3.  Results 
 
3.1  Partial purification of MHC-AF 
 
We previously described a rat factor which induced NK resistance in YAC tumour cells 
and enhanced the expression of class I MHC antigens on these cells (Saxena 1987; 
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Saxena et al 1988a, 1989, 1992). This factor termed NK-RIF was purified from the 
culture supernatants of ion-A activated rat spleen cells. In order to look for a possible 
human counterpart of the rat factor, we fractionated the Con-A supernatant of 
HPBMC. Con-A supernatants were processed and concentrated as described in § 2 and 
then fractionated on a Sephadex G-100 column. All fractions were examined for their 
effect on MHC I antigen expression on HR tumour cells. Figure 1 indicate the elution 
profile of the human MHC-AF from a typical experiment. MHC-AF activity eluted 
towards the end of the major albumin peak. Last few fractions with MHC-AF activity 
had 1 to 5 mg protein per fraction. Fractions with MHC-AF activity were pooled, 
concentrated, dialyzed against 1% glycine for further fractionation by preparative IEF. 
 
Figure 1. Fractionation of human MHC-AF on a Sephadex G100 olumn. Culture super 
natant (0·9 liters) of Con-A—activated HPBMC, was processed as described in § 2. The 
concentrate (30 ml) obtained after pH 2·0 dialysis step and containing 1·1g of protein was 
fractionated on a Sephadex G100 column (5 x 115 cm) using PBS. Fractions of 320 drops were 
collected and assayed for protein by measuring absorbance at 280 nm (O). Each fraction was 
also tested (at 10% v/v) for MHC-AF activity using HR tumour cells as described in §2(?). 
 
Results in figure 2 show a typical IEF profile of MHC-AF. It should be noted that 
dilute fractions obtained from preparative IEF were assessed as such, thus the 
magnitude of effect of MHC-AF is not very high. The isoelectric pH of MHC-AF 
appears to be 6·0. The IEF fractions with MHC-AF activity were pooled, dialyzed 
against 0·1 M Tris-HCl buffer, pH 8·2, concentrated and placed on a HR8 ion-exchange 
HPLC column. This column was developed with a gradient of 20 to 100% v/v of 0·5 M
NaCl. Figure 3 shows that the MHC-AF activity eluted from the HR8 column along 
with the very first protein peak. In order to assess the molecular weight of MHC-AF, 
fractionation on a PP125 sizing HPLC column was used. The elution profile of the 
MHC-AF activity on PP125 column is shown in figure 4. The PP125 column was 
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Figure 2. Preparative isoelectric focusing of MHC-AF activity. Fractions with MHC-AF 
activity obtained after the Sephadex G100 column were pooled, concentrated and dialyzed 
against a 1% glycine solution and fractionated on a flat bed preparative isoelectric focusing set 
up using granulated gel. Each fraction was dialyzed against PBS and tested for MHC-AF 
activity at 5% v/v using K562 tumour cells. 
 
calibrated with different protein markers and from the position of the MHC-AF 
activity peak, its molecular weight appears to be around 35 kDa. SDS page analysis of 
the pooled activity peak from PP125 column showed several protein bands indicating 
that the MHC-AF preparation was not homogeneous at this stage. 
 
3.2  Relationship of MHC-AF to known cytokines 
 
Many cytokines, such as IFN and TNF are known to enhance the class I MHC antigen 
expression on a variety of tumour cell lines. Dose response and time kinetics of 
MHC-AF activity were compared-with those of IFN and TNF. Figures 5 and 6 show 
that TNF and IFN-α and ß had little if any MHC I augmenting effect on HR cells. 
IFN-γ and MHC-AF has similar dose response and time kinetics pattern, although at 
the concentrations tested, MHC-AF appeared to be more potent than IFN-γ. Some 
other cytokines like IL-2, 4, 6 and 7 were also examined and found to be devoid of 
MHC-AF activity. 
Con-A is known to induce IFN-γ production by lymphocytes. However, the 
protocol for purification of MHC-AF included a step of extensive dialysis against pH
2·0, a treatment known to destroy the IFN-γ activity. Moreover, using the WISH 
cell/EMC system, no IFN-like anti-viral activity could be detected in MHC-AF 
preparations. We considered the possibility that pH 2·0 treatment could have abolished
the anti-viral but not the class I MHC augmenting effect of IFN-γ. It was crucial to 
assess this point, since MHC-AF activity might in that case, represent a pH 2·0
"inactivated" IFN-γ. To test this possibility, human recombinant IFN-γ was dialysed 
for two days against 0·1 M glycine-HCI buffer, pH 2·0 and then examined for both 
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Figure 3. Fractiontion of MHC-AF activity on HPLC anion exchange column. An IEF-
purified MHC-AF preparation was fractionated on an anion exchange HPLC column run in 
10 mM Tris HCl  buffer pH 8·2, using a sodium chloride gradient from 20 to 100% of 0·5 M
NaCI (brocken line). Elution profile of proteins is indicated by thin line. Fractions were tested 
for MHC-AF activity on the HR cell line at 10% v/v as described in §2 and the profile of the 
activity is shown in bold line. 
 
anti-viral and class I MHC augmenting activities. These experiments indicated that pH
2·0 treatment resulted in a parallel loss (about 95% loss in each assay) of antiviral and
class I MHC augmenting activity of IFN-γ (results not shown). These results rule out 
the possibility that MHC-AF activity represented a pH 2.0 altered form of IFN-γ. 
To further evaluate the possible relationship of MHC-AF to known cytokines, attempts 
were made to neutralize the MHC-AF activity with antibody preparations capable of 
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Figure 4. Fractionation of MHC-AF activity on HPLCPP125 column. 0·2 ml of a MHC-AF
preparation (400 µg/ml) obtained after the IEF step was fractionated on a PP125 HPLC 
column and the fractions were examined for MHC-AF activity (O) at 10% v/v, using HR cells 
as described in § 2. 
 
neutralizing various types of interferons or TNF. Results of a typical experiment in 
table 1 show that the antibody preparations effectively neutralized the biological 
activities of their respective cytokines. Antibodies to IFN-α and ß and to TNF had no
effect on the biological activity of MHC-AF. Anti IFN-γ had a partial blocking effect 
on MHC-AF activity (table 1). Using both anti-IFN-γ and anti-TNF antibodies did 
not further reduce the effect of MHC-AF preparation. These results indicate that of the 
cytokines examined, MHC-AF activity might have some relationship with IFN-γ. 
Alternatively, the MHC-AF preparation tested might have contained some IFN-γ 
activity as well as MHC-AF activity. This issue was further examined by using an 
anti-IFN-γ affinity column. This affinity column was made by immobilizing 2·5 mg of
an anti IFN-γ monoclonal antibody and a demonstrated capacity to absorb at least 105 
units of IFN-γ. Results in figure 7 indicate that the potency of MHC-AF preparation in 
enhancing class I MHC expression on HR tumour cells was not reduced by passage 
through anti-IFN-γ affinity column. Affinity column passed MHC-AF also has no 
IFN-γ contamination as assessed by biological and immunological assays. MHC-AF 
activity, therefore, may not be ascribed to the presence of IFN-γ. 
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Figure 5. Dose response effect of IFNs, TNF and MHC-AF on class I MHC antigen 
expression on HR cells. HR tumour cells (0·1 x 106/ml) were cultured with various concentra 
tions of IFNs, TNF or MHC-AF preparations. The highest concentration points in the figure 
correspond to 666 U/ml of IFN-α, ß or γ, 0·5 µg/ml of TNF-α and 10 µg/ml of a MHC-AF 
preparation obtained from a HR8 HPLC column. After 2 days of culture, HR cells were 
stained for class I MHC antigens and analysed on a flow cytometer. 
 
4.  Discussion 
 
We report here the partial purification and characterization of a factor from the culture 
supernatants of Con-A activated HPBMSs, which augments the expression of class 
I MHC antigens on tumour cells. A similar class I MHC expression-augmenting factor 
was previously reported to be released by mitogen-activated rat spleen cells (Saxena 
1987; Saxena et al 1988a, 1989, 1992). The rat factor was, however, initially identified by 
its property of inducing NK resistance in YAC tumour cells, and this bioassay was used 
for its purification and characterization (Saxena et al 1988a). For this reason, the rat 
factor was named as NK-RIF. Purified preparations of rat NK-RIF were also found to 
augment the expression of class I MHC antigen on YAC tumour cells (Saxena et al 
1988a, 1992). While looking for the human equivalent of the rat factor, we used MHC 
I augmentation as a primary bioassay and, therefore, have referred to it as MHC-AF 
rather than NK-RIF. Purified MHC-AF preparation could induce NK resistance in 
K562 tumour cells (results not shown). although we cannot be certain at present 
whether a single molecule is responsible for MHC-AF and NK-RIF activities. 
Human MHC-AF was partially purified on gel filtration followed by preparative 
IEF and further purification on HPLC ion-exchange and sizing columns. The molecular 
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Figure 6. Kinetics of the effect of MHC-AF and IFNs on the expression of class I MHC 
antigens on HR tumour cells. HR tumour cells were initiated in culture at 0·1 x 106 cells/ml. 
Various IFNs (400 U/ml) or MHC-AF preparation obtained from a HR8 HPLC column 
(1 µg/ml) were added to the cultures at different time points so that at the time of harvesting 
(48 h), cells had been exposed to the agents for varying periods of time. HR cells were stained 
for the class I MHC antigen expression and analysed by flowcytometer. 
 
weight of MHC-AF was around 35 kDa with a pI of 6·0. As indicated in results,
MHC-AF preparation obtained after final purification step of PP125 column, was still 
not homogeneous. We think that the presence of fetal calf serum in the initial culture 
medium introduces a large amount of a complex mixture of irrelevant proteins, which 
makes it difficult to obtain a homogeneous preparation of MHC-AF. It will be 
necessary to devise procedure for generating this factor in serum free medium in order 
to get a homogeneously pure MHC-AF. Attempts are currently underway to standar-
dize procedure for generating MHC-AF in serum free medium. 
The crucial issue is whether MHC-AF is one of the known cytokines or a novel 
factor. IFN and TNF can augment the expression of class I MHC antigens on tumour 
cells (Weber and Rosenberg 1988; Mortarini et al 1990). IFN-α and ß as well as TNF-α 
are, however, relatively poor inducers of MHC antigens. Moreover, neutralizing 
antibodies to TNF and IFN-α or ß, had no effect on the class I MHC augmenting 
activity of MHC-AF preparations. These results would seem to rule out IFN-α and 
ß and TNF-α as entities responsible for the MHC-AF activity. The possible relation- 
ship of MHC-AF to IFN-γ was of particular concern. IFN-γ is known to most 
effectively induce MHC I antigen expression on tumour cells. Moreover, antibodies to 
IFN-γ could at least partially neutralize the MHi-AF activity. Even though the 
MHC-AF preparations were devoid of any activity in anti-viral bioassays for IFNs and 
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Table 1. Effect of antibodies to IFN or TNF on MHC-AF 
activity. 
 
K562 tumour cells were treated with various combinations of 
reagents for 3 days under conditions described in §2. All IFNs 
and TNF were used at 100 U/ml concentration and all antisera 
were added to a concentration sufficient to neutralize 500 U/ml of 
their respective cytokine. A MHC-AF preparation obtained by 
IEF was used at a final concentration of 10 µg/ml. The tumour 
cells were examined for expression of class I MHC antigens by 
flowcytometry. 
 
the purification protocol of MHC-AF included a step of pH 2·0 dialysis for 2 days, 
a treatment which is known to inactivate IFN-γ, the possibility exsited that the pH 2·0 
treatment abolished the antiviral activity of IFN-γ in Con-A supernatants without 
influencing its MHC augmenting activity. This crucial issue was, therefore, examined 
by evaluating the antiviral as well as the class I MHC augmenting effects of IFN-γ, 
before and after pH 2·0 dialysis. Our results indicated that pH 2·0 treatment destroyed 
both these activates of IFN-γ. The activity of MHC-AF preparations could, therefore, 
not be attributed to the presence of pH 2·0-exposed IFN-γ. In addition, an affinity 
column with immobilized Mabs to IFN-γ with proven efficacy to absorb IFN-γ, did not 
show any significant absorption of MHC-AF activity, even though the affinity column- 
assed MHC-AF preparation had no biologically or immunologically active IFN-γ. 
Taking these data together, it appears quite unlikely that IFN-γ is responsible for the 
potent MHC I expression augmenting activity in MHC-AF preparations. Nonetheless, 
in view of an apparent partial neutralization of MHC-AF activity by anti-IFN-γ 
antibodies, it is possible that the effect of MHC-AF may, at least partially, be mediated 
through IFN-γ or some other factor that is cross-reactive with IFN-γ. Definitive 
resolution of this issue will require further characterization of MHC-AF. 
The class I MHC antigen expression on tumour cells in vivo may be an important 
factor in determining the susceptibility of these cells to immunosurveillance mechanisms. 
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Figure 7. Retention of IFN-γ but not of human MHC-AF on a human IFN-γ affinity 
column. One ml of human recombinant IFN-γ  preparation (10,000 U/ml) was passed through 
an anti-IFN-γ affinity column. A MHC-AF preparation obtained after the HR8 HPLC 
fractionation (24 µg/ml) was also passed through the affinity column. Preparations of IFN (A) 
or MHC-AF (B) before (?) and after (O) absorption on the affinity column, were tested at 
various concentration, for their effect on class I MHC antigen expression on HR tumour cells 
as described in § 2. 
 
Moreover, the immuno-therapeutic potential of experimental infusion of in vitro 
expanded tumour infiltrating lymphocytes (TILs), might be enhanced by protocols 
which would sustain, or even boost the expression of class I MHC antigens on tumour 
cells in vivo. In this context, cytokines like TNF and IFN alone or in combination are 
currently being examined for their class I MHC boosting property (Weber and 
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Rosenberg 1988; Mortarini et al 1990). MHC-AF is a potent inducer of class I MHC 
antigen expression in vitro. It will be of interest to examine the efficacy of MHC-AF for 
tumour class I MHC expression augmentation in vivo. 
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